DETROIT & BOSTON, December 04, 2025--(BUSINESS WIRE)--Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s ...
DURHAM, N.C., November 25, 2025--(BUSINESS WIRE)--Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of ...
Amgen has reported positive results from its phase 3 VESALIUS-CV trial, which demonstrated that Repatha (evolocumab) significantly reduced the risk of first-time major adverse cardiovascular events ...
Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
A new mold concept developed by Zahoransky is engineered to accelerate the mass production of housings for insulin pens and auto injectors in a space- and energy-efficient manner. The Z.Sonic turn ...
Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Democrats achieved the worst ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved ...
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection ...
Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...
LOS ANGELES, Oct 6 (Reuters) - Amgen (AMGN.O), opens new tab on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results